USPTO Examiner CHEN STACY BROWN - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18645951METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645961METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645942METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18641205COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERYApril 2024February 2025Allow1010NoNo
18438342COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTIONFebruary 2024December 2024Allow1011YesNo
18500970INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTIONNovember 2023July 2025Allow2111YesNo
18499857ADOPTIVE CELL TRANSFER AND ONCOLYTIC VIRUS COMBINATION THERAPYNovember 2023June 2025Abandon1910NoNo
18385879COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONSOctober 2023August 2024Allow1021YesNo
18462340RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USESeptember 2023October 2024Allow1300NoNo
18242025ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAMESeptember 2023March 2025Abandon1910NoNo
18339553METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODSJune 2023April 2025Abandon2201NoNo
18329441NEUTRALIZING ANTIBODY IMMUNOASSAYSJune 2023May 2025Abandon2301NoNo
18328403Compositions for Booster Vaccination Against DengueJune 2023July 2025Abandon2620YesNo
18327882CORONAVIRUS VACCINEJune 2023September 2023Allow430YesNo
18142988AAV CAPSID PRODUCTION IN INSECT CELLSMay 2023April 2025Abandon2311NoNo
18308934HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONApril 2023April 2025Allow2421YesNo
18098949SAPONIN PURIFICATIONJanuary 2023October 2024Allow2110YesNo
18085110VIRUS PURIFICATION AND FORMULATION PROCESSDecember 2022January 2025Allow2511YesNo
18052178NUCLEIC ACID VACCINES FOR CORONAVIRUSNovember 2022January 2025Abandon2710NoNo
18051819NUCLEIC ACID VACCINES FOR CORONAVIRUSNovember 2022January 2025Abandon2710NoNo
17970036COMPOSITIONS AND METHODS FOR DELIVERY OF AAVOctober 2022December 2024Allow2610NoNo
18046243Compositions and Administration of Chimeric Glycoprotein Lyssavirus Vaccines for Coverage Against RabiesOctober 2022July 2025Abandon3311NoNo
17869306HCoV IMMUNOGENIC BOOSTER COMPOSITION FOR IMPROVING IMMUNITYAGAINST SARS-COV-2 INFECTIONJuly 2022October 2024Allow2710YesNo
17857303Virus-Like Particle ConjugatesJuly 2022January 2025Allow3110NoNo
17856774MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONSJuly 2022October 2024Allow2710YesNo
17851492SAPOVIRUS VACCINESJune 2022June 2025Allow3610YesNo
17839401HUMAN CYTOMEGALOVIRUS VACCINEJune 2022October 2024Abandon2910NoNo
17837294COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCERJune 2022April 2025Allow3411YesNo
17709599COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITYMarch 2022July 2024Allow2810YesNo
17575462USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORSJanuary 2022April 2025Allow4030YesNo
17613602PHARMACEUTICAL COMPOSITIONS TO ENHANCE PHAGOCYTOSIS WITHOUT INFLAMMATIONNovember 2021July 2025Abandon4401NoNo
17613011DRUG-RESISTANT INFLUENZA VIRUS STRAINSNovember 2021July 2025Abandon4401NoNo
17610026ATTENUATED YELLOW FEVER VIRUS AND USES THEREOF FOR THE TREATMENT OF CANCERNovember 2021July 2025Abandon4401NoNo
17609217INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONSNovember 2021June 2025Abandon4410NoNo
17607213VECTORIZED ANTIBODIES (vAb) AND USES THEREOFOctober 2021September 2025Abandon4711NoNo
17512246SYSTEMS AND METHODS FOR ULTRA-SPECIFIC AND ULTRA-SENSITIVE NUCLEIC ACID DETECTIONOctober 2021March 2025Allow4010YesNo
17487690MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINSSeptember 2021July 2024Allow3411NoNo
17442871IMMUNOCHROMATOGRAPHIC ASSAY METHOD, AND TEST STRIP USED IN SAID IMMUNOCHROMATOGRAPHIC ASSAY METHODSeptember 2021March 2025Abandon4210NoNo
17478537Compositions and Methods for Dengue Virus Chimeric Constructions in VaccinesSeptember 2021May 2024Allow3221YesNo
17404143Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using SameAugust 2021October 2024Allow3820YesNo
17401079Rapid Viral Diagnostic TestAugust 2021April 2025Abandon4421NoNo
17386644VIRAL VECTOR ASSAY AND VECTORJuly 2021November 2024Allow4021YesNo
17385416THERMAL INACTIVATION OF ROTAVIRUSJuly 2021March 2025Abandon4421YesNo
17372044BOVINE HERPESVIRUS TYPE 1 (BOHV-1) VECTOR AGAINST BOVINE RESPIRATORY DISEASE COMPLEXJuly 2021January 2025Allow4220NoNo
17357368VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSESJune 2021February 2025Abandon4331YesNo
17325149METHOD AND COMPOSITION FOR AMELIORATING AND ABATING SYMPTOMS RESULTING FROM RHEUMATOID ARTHRITIS, FIBROMYALGIA, AND CHRONIC PAIN OF UNKNOWN ORIGINMay 2021August 2025Abandon5130NoNo
17246364VIRAL SEROLOGY ASSAYSApril 2021July 2025Abandon5021NoNo
17232751NANO-SATELLITE COMPLEXESApril 2021October 2024Allow4211YesNo
17276788CORONAVIRUS VACCINEMarch 2021November 2024Allow4410YesNo
17172300COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOFFebruary 2021January 2025Abandon4741NoNo
17266049RECOMBINANT BIOLOGICALLY CONTAINED FILOVIRUS VACCINEFebruary 2021January 2025Allow4740YesNo
17264370METHODS AND COMPOSITIONS TO DETECT MICROBES AND VIRAL PARTICLESJanuary 2021August 2025Abandon5421NoNo
16972077ANTIBODIES OR ANTIBODY-FRAGMENTS THEREOF TARGETING ALPHAVIRUSES, AND COMPOSITIONS AND METHODS COMPRISING SAMEDecember 2020August 2024Allow4531YesNo
17059882TARGETING P18 FOR mTOR-RELATED DISORDERSNovember 2020September 2024Allow4511YesNo
17097687METHOD FOR DETERMINING THE SENSITIVITY OF A BACTERIAL STRAIN TO A BACTERIOPHAGENovember 2020December 2024Allow4940YesNo
17047611BACTERIOPHAGE COMPOSITIONSOctober 2020February 2025Allow5231NoNo
17040455IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODSSeptember 2020August 2024Allow4711NoNo
16981197SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULESSeptember 2020February 2025Allow5331YesNo
16976220ATTENUATED FLAVIVIRUSESAugust 2020August 2024Allow4831YesNo
16755257MAYARO VIRUS CONSENSUS ANTIGENS, DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MAYARO VIRUS, AND COMBINATIONS THEREOFApril 2020September 2024Allow5361YesNo
15682341METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIESAugust 2017November 2024Abandon6090YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner CHEN, STACY BROWN - Prosecution Strategy Guide

Executive Summary

Examiner CHEN, STACY BROWN works in Art Unit 1671 and has examined 31 patent applications in our dataset. With an allowance rate of 54.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner CHEN, STACY BROWN's allowance rate of 54.8% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHEN, STACY BROWN receive 2.26 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.